Skip to main content
. Author manuscript; available in PMC: 2020 Jun 10.
Published in final edited form as: J Control Release. 2019 Apr 9;303:42–54. doi: 10.1016/j.jconrel.2019.04.008

Figure 1. Doxorubicin increased type I interferon production in murine cancer cell lines and immunogenic cell death in NDL cells.

Figure 1.

In vitro release of IFN-α (A), IFN-β (B) in NDL and 4T1 murine mammary carcinoma, mT4 murine pancreatic cancer, MC-38 murine colon cancer cells, B16 murine melanoma, and HMGB 1 in NDL cell culture 24 h post treatment, respectively. Cells were preincubated for 5 min (type I IFN) or 1 min (HMGB 1) at 42°C prior to addition of media only (42°C) or a solution of 5 µg/mL Dox in media (Free Dox+42°C) at 42°C for another 5 min. * p < 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001.